SHIMADZU BIOTECH APPOINTS NEW MALDI GLOBAL BUSINESS MANAGER

Key role helps unite proteomics and drug discovery provision

Shimadzu Biotech, the recently launched business unit of Shimadzu Corporation has promoted Dr Chris Sutton to the position of Global Business Manager for MALDI instruments. This move will further propel the unit's strategy to integrate products from Shimadzu and their subsidiary Kratos Analytical.

Dr Sutton joined Kratos Analytical in April 1998 as MALDI (matrix-assisted laser desorption ionisation) Product Manager, during which time he promoted the Kompact series of MALDI mass spectrometry instruments. "My experience in this area has allowed me to become a primary influence on the design and performance of the next generation of MALDI mass spectrometers," Dr Sutton commented. "As Global Business Manager I look forward to seeing Shimadzu Biotech become the key provider of analytical solutions for life science and drug discovery," he added.

In this new role, Dr Sutton will hold global responsibility for MALDI MS business including sales & marketing, applications, engineering and research & development. He will be based at the Kratos Analytical facility in Manchester, UK.

Shimadzu Biotech aims to provide solutions-based products to accelerate the progress of biotechnology research and development. Along with the new AXIMA series of MALDI-TOF (MALDI Time-Of-Flight) mass spectrometers for proteomics and genomics, Shimadzu Biotech will also be supporting combinatorial chemistry, micro-satellite DNA and SNP analysis applications.

- ends -

For more information, please contact:

Shimadzu Biotech
Chris Sutton, MALDI Business Manager
Fax: +44 (0)161 888 4402 ext 228
Tel: +44 (0)161 888 4400
email: chris.sutton@kratos.co.uk
Website: http://www.shimadzu-biotech.net

For press information, please contact:

HCC De Facto Group plc
Richard Anderson
Tel: +44 (0)20 7496 3300
Fax: +44 (0)20 7496 3355
email: r.anderson@hccdefacto.com